Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (8226)	9/14/2000 1:44:06 PM
From: satish kamat	Read Replies (1) \| Respond to of 9719

Wondering if you have looked at SCLN? Here is a company which have relatively little or no debt, actual product revenues from a product that is in multiple phase II and III trials for other indications and already in use in ~20 countries other than USA. Some say it is dubious drug. Would welcome opinion on this company. satish kamat biz.yahoo.com SciClone is a global biopharmaceutical company that acquires, develops and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases. For the six months ended 6/00, revenues increased 98% to $7.7 million. Net loss decreased 65% to $1.5 million. Results reflect increased sales of ZADAXIN due to greater distribution in China. Lower loss reflects decreased clinical trials expense, consulting fees and payroll expense